These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [To which criterion should the dosage of anticancer drug be adapted?]. Desoize B Bull Cancer; 1993 May; 80(5):376-90. PubMed ID: 8173191 [TBL] [Abstract][Full Text] [Related]
3. Practical treatment guide for dose individualisation in cancer chemotherapy. Canal P; Chatelut E; Guichard S Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990 [TBL] [Abstract][Full Text] [Related]
4. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Rousseau A; Marquet P Fundam Clin Pharmacol; 2002 Aug; 16(4):253-62. PubMed ID: 12570013 [TBL] [Abstract][Full Text] [Related]
5. [Dose expression of antineoplastic drugs]. Favre R; Duffaud F; Erard G Rev Med Interne; 1996; 17(7):586-96. PubMed ID: 8881387 [TBL] [Abstract][Full Text] [Related]
6. Tailor-made chemotherapy for cancer patients. van Warmerdam LJ Neth J Med; 1997 Jul; 51(1):30-5. PubMed ID: 9260487 [TBL] [Abstract][Full Text] [Related]
8. [Anticancer drug dose individualisation: from body surface area to physiology]. Pétain A; Chatelut E Bull Cancer; 2008 Oct; 95(10):895-901. PubMed ID: 19004718 [TBL] [Abstract][Full Text] [Related]
9. Adaptive control methods for the dose individualisation of anticancer agents. Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455 [TBL] [Abstract][Full Text] [Related]
10. Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy. Canal P; Gamelin E; Vassal G; Robert J Pathol Oncol Res; 1998; 4(3):171-8. PubMed ID: 9761935 [TBL] [Abstract][Full Text] [Related]
11. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Felici A; Verweij J; Sparreboom A Eur J Cancer; 2002 Sep; 38(13):1677-84. PubMed ID: 12175683 [TBL] [Abstract][Full Text] [Related]
12. Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan. Kouno T; Katsumata N; Mukai H; Ando M; Watanabe T Jpn J Clin Oncol; 2003 Jun; 33(6):309-13. PubMed ID: 12913086 [TBL] [Abstract][Full Text] [Related]
13. Body surface area in dosing anticancer agents: scratch the surface! Miller AA J Natl Cancer Inst; 2002 Dec; 94(24):1822-3. PubMed ID: 12488468 [No Abstract] [Full Text] [Related]
14. Can pharmacokinetic and pharmacodynamic studies improve cancer chemotherapy? Newell DR Ann Oncol; 1994; 5 Suppl 4():9-14; discussion 15. PubMed ID: 8060901 [TBL] [Abstract][Full Text] [Related]
15. The scientific basis of body surface area-based dosing. Chatelut E; Puisset F Clin Pharmacol Ther; 2014 Apr; 95(4):359-61. PubMed ID: 24646485 [No Abstract] [Full Text] [Related]
16. Scaling laws for plasma concentrations and tolerable doses of anticancer drugs. Dawson TH Cancer Res; 2010 Jun; 70(12):4801-8. PubMed ID: 20530681 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetically guided administration of chemotherapeutic agents. van den Bongard HJ; Mathôt RA; Beijnen JH; Schellens JH Clin Pharmacokinet; 2000 Nov; 39(5):345-67. PubMed ID: 11108434 [TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetics and individual dose adjustment of carboplatin]. Chatelut E; Canal P; Bugat R Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718 [TBL] [Abstract][Full Text] [Related]
19. [Correlations between clinical pharmacodynamics and pharmacokinetics of cisplatin and etoposide]. Desoize B; Maréchal F; Cattan A Ann Biol Clin (Paris); 1993; 51(2):125-8. PubMed ID: 8214810 [TBL] [Abstract][Full Text] [Related]
20. [Use of body weight and body surface area in dosing of anticancer agents in adult patients]. Levêque D Bull Cancer; 2007 Jul; 94(7):647-51. PubMed ID: 17723945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]